Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Felix Stader, Saye Khoo, Marcel Stoeckle, David Back, Hans H. Hirsch, Manuel Battegay, Catia Marzolini
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious, causing coronavirus infectious disease 2019 (COVID-19) worldwide. 1 One of the experimental treatments includes the HIV drug lopinavir boosted with ritonavir. Both PIs
Topics & Concepts
LopinavirRitonavirLopinavir/ritonavirCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyDrugCoronavirusInfectious disease (medical specialty)PharmacologyInternal medicineViral loadHuman immunodeficiency virus (HIV)DiseaseAntiretroviral therapyOutbreakCOVID-19 Clinical Research StudiesAntibiotics Pharmacokinetics and EfficacyPharmacological Receptor Mechanisms and Effects